Oxford Ledge
Search
No licensed closing price on file for AMLX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:13 UTC.
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases with high unmet medical needs. The company's lead investigational asset is avexitide, a first-in-class GLP-1 receptor antagonist being evaluated for post-bariatric hypoglycemia and congenital hyperinsulinism, both conditions characterized by excessive insulin causing dangerously low blood sugar. Avexitide has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation from the FDA.
Summarized from Amylyx Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| Return on equity | -183.14% |
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases with high unmet medical needs.
Amylyx Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-04. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:13 UTC. This page is also available as JSON at /api/data?ticker=AMLX and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for AMLX and 5,000+ tickers.
Create a free account — keep AMLXGET /api/data?ticker=AMLX
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt